RxDoctor Payments Data

Aijaz Turk

Gastroenterology · Kalamazoo, MINPI 1689636367

Payments from drug & device makers

$3,015in general payments, 2019–2025

Across 139 payments — averaging $21.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$625
  • AbbVie$500
  • Takeda Pharmaceuticals U.S.A., Inc.$344
  • Johnson & Johnson$198
  • Pfizer$197
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$192
  • plus $959 from 18 others

What the payments were for

  • Food & beverage$2,96898%
  • Education$472%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,015 in reported general payments places this provider in the 55th percentile of 497 gastroenterology providers in Michigan.

See all gastroenterology providers in Michigan

Medicare billing

Part B allowed, 2024
$63,085
Medicare patients
315
Services billed
585

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab24$176,246
Humira PenAdalimumab13$83,532
CreonLipase/Protease/Amylase12$54,323
Mesalamine39$11,508
LinzessLinaclotide17$11,431
Omeprazole238$2,641
Azathioprine24$2,229
Ursodiol13$943
Pantoprazole Sodium68$867
Famotidine48$592
LoperamideLoperamide Hcl12$492
Sulfasalazine15$461
Mercaptopurine11$371
Nadolol12$278

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$500$65,75329 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 497 gastroenterology providers in Michigan.

Other gastroenterology in Kalamazoo

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →